Loading...
Loading...
Compare original and translation side by side
PDBeSIFTS_get_best_structuresRCSBGraphQL_get_structure_summaryalphafold_get_summaryPDBe_get_structure_ligandsBindingDB_get_ligands_by_uniprotProteinsPlus_predict_binding_sitesPDBeSIFTS_get_best_structuresRCSBGraphQL_get_structure_summaryalphafold_get_summaryPDBe_get_structure_ligandsBindingDB_get_ligands_by_uniprotProteinsPlus_predict_binding_sitesRCSBAdvSearch_search_structuresRCSBData_get_entryRCSBGraphQL_get_structure_summaryRCSBGraphQL_get_ligand_infoRCSB_get_chemical_componentRCSBAdvSearch_search_structuresRCSBData_get_entryRCSBGraphQL_get_structure_summaryRCSBGraphQL_get_ligand_infoRCSB_get_chemical_componentpdbe_get_entry_summaryPDBe_get_structure_ligandsPDBe_get_bound_moleculesPDBeSearch_search_structuresPDBeSIFTS_get_best_structuresPDBeSIFTS_get_all_structuresPDBe_KB_get_ligand_sitesPDBe_KB_get_interface_residuesPDBeValidation_get_quality_scorespdbe_get_entry_summaryPDBe_get_structure_ligandsPDBe_get_bound_moleculesPDBeSearch_search_structuresPDBeSIFTS_get_best_structuresPDBeSIFTS_get_all_structuresPDBe_KB_get_ligand_sitesPDBe_KB_get_interface_residuesPDBeValidation_get_quality_scoresPDBePISA_get_interfacesPDBePISA_get_assembliesPDBePISA_get_interfacesPDBePISA_get_assembliesalphafold_get_predictionalphafold_get_summaryalphafold_get_annotationsalphafold_get_predictionalphafold_get_summaryalphafold_get_annotationsProteinsPlus_predict_binding_sitesBindingDB_get_ligands_by_uniprotBindingDB_get_ligands_by_pdbBindingDB_get_targets_by_compoundProteinsPlus_predict_binding_sitesBindingDB_get_ligands_by_uniprotBindingDB_get_ligands_by_pdbBindingDB_get_targets_by_compoundFoldseek_search_structureFoldseek_get_resultFoldseek_search_structureFoldseek_get_resultGPCRdb_get_proteinGPCRdb_get_structuresGPCRdb_get_ligandsGPCRdb_get_mutations{symbol.lower()}_humanGPCRdb_get_proteinGPCRdb_get_structuresGPCRdb_get_ligandsGPCRdb_get_mutations{symbol.lower()}_humanSAbDab_search_structuresSAbDab_get_structureTheraSAbDab_search_therapeuticsTheraSAbDab_search_by_targetSAbDab_search_structuresSAbDab_get_structureTheraSAbDab_search_therapeuticsTheraSAbDab_search_by_targetInterPro_get_protein_domainsPfam_get_protein_annotationsUniProt_get_entry_by_accessionInterPro_get_protein_domainsPfam_get_protein_annotationsUniProt_get_entry_by_accessionProteomeXchange_search_datasetsProteomeXchange_get_datasetProteomeXchange_search_datasetsProteomeXchange_get_datasetPhase 0: Resolve protein → UniProt ID, gene symbol, organism
Phase 1: PDBeSIFTS_get_best_structures → RCSBGraphQL_get_structure_summary → PDBeValidation
Phase 2: alphafold_get_prediction/summary → compare pLDDT with experimental coverage
Phase 3: IF GPCR → GPCRdb; IF antibody target → SAbDab/TheraSAbDab
Phase 4: InterPro/Pfam domain mapping → identify unresolved regions
Phase 5: Summary table (PDB ID, method, resolution, ligands, coverage, quality)Phase 0: 解析蛋白质 → UniProt ID、基因符号、物种
Phase 1: PDBeSIFTS_get_best_structures → RCSBGraphQL_get_structure_summary → PDBeValidation
Phase 2: alphafold_get_prediction/summary → 对比pLDDT与实验覆盖范围
Phase 3: 若为GPCR → GPCRdb;若为抗体靶点 → SAbDab/TheraSAbDab
Phase 4: InterPro/Pfam结构域映射 → 识别未解析区域
Phase 5: 汇总表格(PDB ID、方法、分辨率、配体、覆盖范围、质量)Phase 1: PDBe_get_structure_ligands + RCSBGraphQL_get_ligand_info + PDBe_KB_get_ligand_sites
Phase 2: ProteinsPlus_predict_binding_sites → druggability score, pocket residues
Phase 3: BindingDB_get_ligands_by_pdb/uniprot → Ki, Kd, IC50
Phase 4: RCSB_get_chemical_component for key ligandsPhase 1: PDBe_get_structure_ligands + RCSBGraphQL_get_ligand_info + PDBe_KB_get_ligand_sites
Phase 2: ProteinsPlus_predict_binding_sites → 成药性评分、口袋残基
Phase 3: BindingDB_get_ligands_by_pdb/uniprot → Ki、Kd、IC50
Phase 4: RCSB_get_chemical_component 获取关键配体信息Phase 1: Find co-crystal structures → filter for drug/analogs
Phase 2: BindingDB affinity data (Ki, Kd, IC50)
Phase 3: ProteinsPlus + PDBe-KB binding site characterization
Phase 4: PDBeValidation quality → binding site well-resolved?
Phase 5: AlphaFold + Foldseek structural comparison
Phase 6: GPCR-specific (if applicable) → active/inactive states, pharmacology, resistance mutations
Phase 7: Antibody-specific (if applicable) → epitope mapping
Phase 8: Evidence integrationPhase 1: 查找共晶结构 → 筛选药物/类似物
Phase 2: BindingDB亲和力数据(Ki、Kd、IC50)
Phase 3: ProteinsPlus + PDBe-KB结合位点特征分析
Phase 4: PDBeValidation质量评估 → 结合位点是否解析良好?
Phase 5: AlphaFold + Foldseek结构对比
Phase 6: 若为GPCR特异性 → 活性/非活性状态、药理学、耐药突变
Phase 7: 若为抗体特异性 → 表位定位
Phase 8: 整合证据| Tool | Mistake | Correct |
|---|---|---|
| | |
| | |
| gene symbol | |
| | |
| | |
| | |
| 工具 | 常见错误 | 正确用法 |
|---|---|---|
| 使用 | 使用 |
| 使用 | 使用 |
| 使用基因符号 | 使用 |
| 使用 | 使用 |
| 使用 | 使用 |
| 使用 | 使用 |
| Tier | Confidence |
|---|---|
| T1 | Co-crystal (<2.5A) + binding affinity data |
| T2 | Experimental structure + computational prediction |
| T3 | AlphaFold + pocket analysis + known ligand analogs |
| T4 | Homology model or low-resolution only |
| 等级 | 置信度 |
|---|---|
| T1 | 共晶结构(<2.5Å)+ 结合亲和力数据 |
| T2 | 实验结构 + 计算预测 |
| T3 | AlphaFold + 口袋分析 + 已知配体类似物 |
| T4 | 仅同源模型或低分辨率结构 |
| Metric | High | Acceptable | Caution |
|---|---|---|---|
| Resolution | <2.0A (X-ray) / <3.0A (cryo-EM) | 2.0-2.5A / 3.0-4.0A | >3.0A / >4.5A |
| R-free | <0.25 | 0.25-0.30 | >0.30 |
| AlphaFold pLDDT | >90 | 70-90 | <70 (disordered) |
| 指标 | 优秀 | 可接受 | 需谨慎 |
|---|---|---|---|
| 分辨率 | <2.0Å(X射线)/ <3.0Å(冷冻电镜) | 2.0-2.5Å / 3.0-4.0Å | >3.0Å / >4.5Å |
| R-free | <0.25 | 0.25-0.30 | >0.30 |
| AlphaFold pLDDT | >90 | 70-90 | <70(无序区域) |
operationoperation